

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Bruce L. Daugherty, et al.

Serial No.:

10/767,521

Case No.: 19634YDACA

Art Unit: 1646

Filed:

January 29, 2004

Examiner:

For:

NUCLEIC ACID ENCODING EOSINOPHIL

EOTAXIN RECEPTOR

Prema Maria Mertz

The Assistant Commissioner of Patents and Trademarks Washington, D.C. 20231

RESPONSE

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed August 10, 2004, having a 2-month response period due to expire on October 12, 2004, Applicants enclose herewith an amended "Sequence Listing" in paper form. Please replace the existing "Sequence Listing" on pages 36-42 with the enclosed version. The amended "Sequence Listing" contains no new matter.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By: Astry Rupolds Date: 10.8.04

USSN: 10/767,521

Merck Case No.: 19634YDACA

Page 2

The amended "Sequence Listing" in computer readable form is also submitted herewith. The content of the sequence listing information recorded in computer readable form is identical to the written (paper) sequence listing, and contains no new matter

Respectfully submitted,

By:

Mollie M. Yang

Reg. No. 32,718

Attorney for Applicants

MERCK & CO., INC. Patent Department

P.O. Box 2000 Rahway, NJ 07065-0907

Phone: (732) 594-6343

Facsimile: (732) 594-4720

Dated: October 8, 2004

Encl: Sequence Listing (in paper)

Sequence Listing (computer readable form)

Copy of Notice mailed 8/10/2004





United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE UNITED STATES DEFARINGENT OF COMMU United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.usplu.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/767,521

01/29/2004

Bruce L. Daugherty

19634YDACA

000210 MERCK AND CO INC P O BOX 2000 RAHWAY, NJ 070650907



CONFIRMATION NO. 5530 FORMALITIES LETTER *OC000000013492622*

Date Mailed: 08/10/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8. 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450 Alexandria VA 22313-1450

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE